Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

European Commission Approves Injectable Rituximab for Chronic Lymphocytic Leukemia

December 30, 2021

The European Commission approved subcutaneous rituximab for the treatment of previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL).

The approval was based the results of the phase Ib SAWYER study that included untreated CLL patients who received 1,600 mg of subcutaneous rituximab or 500 mg/m2 of rituximab administered intravenously in combination with fludarabine and cyclophosphamide. Patients in each group had comparable levels of serum concentrations, as well as similar efficacy and safety.

Source: Roche media release, May 31, 2016.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals